Overview

A Study to Investigate the Effect of Single and Repeated Oral Doses of ACT-539313 on What the Body Does to Flurbiprofen, Omeprazole, Midazolam in Healthy Subjects

Status:
Not yet recruiting

Trial end date:
2022-04-01

Target enrollment:

Participant gender:

Summary

A study to investigate the effect of single and repeated oral doses of ACT-539313 on what the body does to flurbiprofen, omeprazole, midazolam in healthy participants.

Phase:

Phase 1

Details

Lead Sponsor:

Idorsia Pharmaceuticals Ltd.

Treatments:

Flurbiprofen
Midazolam
Omeprazole